[1]胡晓琳,张海燕.Graves’病患者促甲状腺素受体抗体和甲状腺刺激免疫球蛋白水平的变化及临床意义[J].国际放射医学核医学杂志,2006,30(6):350-352.
　HU Xiao-lin,ZHANG Hal-yan.Clinical significance and changes of TRAb and TSI assay in patients with Graves’ disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(6):350-352.
点击复制

Graves’病患者促甲状腺素受体抗体和甲状腺刺激免疫球蛋白水平的变化及临床意义(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
30
期数:
2006年第6期
页码:
350-352
栏目:
临床核医学
出版日期:
1900-01-01

文章信息/Info

Title:
Clinical significance and changes of TRAb and TSI assay in patients with Graves’ disease
作者:
胡晓琳;  张海燕
300193 天津, 天津中医学院第一附属医院检验科
Author(s):
HU Xiao-lin;  ZHANG Hal-yan
Department of Clinical Laboratory, the First Affdiated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China
关键词:
格雷夫斯病; 甲状腺炎; 自身免疫性; 免疫球蛋白类; 甲状腺刺激; 抗体; 促甲状腺素受体
Keywords:
Graves’ disease; Thyroiditis;  autoimmune; Antibody;  thyrotropic homonereceptor; Immunoglobulins;  thyroid stimulating
分类号:
R817.4
摘要:
目的 探讨Graves’病患者促甲状腺素受体抗体(TRAb)和甲状腺刺激免疫球蛋白(TSI)水平的变化及临床意义。方法 对正常对照组、Graves’病发作组及缓解组、桥本甲状腺炎组分别进行TRAb、TSI及甲状腺功能检测,其中抗体检测采用酶联免疫法或放射免疫法,甲状腺功能检测采用微粒子发光技术。结果 Graves’发作组TRAb、TSI阳性率分别为86.67%和95.00%,桥本甲状腺炎组甲状腺球蛋白抗体(TGA)和甲状腺微粒体抗体(TMA)维持较高水平。阳性率分别达到85.29%和91.18%。与正常对照组比较均有显著性差异。结论 TRAb、TSI、TGA和TMA联合检测,结合甲状腺功能指标。对Graves’病的疗效监测和预后判断有着非常重要的使用价值,并对与桥本甲状腺炎病的鉴别诊断起着很重要的作用。
Abstract:
Objective To explore the changes and clinical significance Of TRAb and TSI detection in patients with Graves’ disease. Methods Serum TRAb and TSI levels were detected by enzyme-linked immunesorbent assay, and thyroid hormone levels were detected by micropaticle enzyme immuneoassay, including normal controls, Graves’ disease in period of onset catabsis group and hashimotos thyroiditis group. Results The positive rate of TRAb and TSI in Graves’ in period of onset group is 86.67% and 95.0%, TGA and TMA in hashimotes thyroiditis group is 85.29% and 91.18%, respectively. More importantly these results were significant difference than normol controls. Conclusions It’s very important for Graves’ disease patients to detect TRAb, TSI, TGA, TMA and thyroid hormone simulta-neously, especially to the curative effect and prognosis criterin in patients with Graves’ disease and antidi-astole in patients with hashimotos thyroiditis.

参考文献/References:

1 刘霞,谭萍,曾自如.Graves’患者血清TRAb检测的临床意义.广西医科大学学报,2005,22(1):45-46.
2 兰玲,施秉银.甲状腺素受体抗体检测的临床意义.国外医学内分泌学分册,2005,25(1):42-44.
3 邓爱民,林延德,王国华.Graves’病患者血清TRAb检测及临床意义.广东医学,2002,23(4):398-399.
4 黄昭穗,黄春红,刘开渊,等.TRAb检测在Graves’甲亢诊断治疗中的价值.放射免疫学杂志,2005,18(2):88-89.

相似文献/References:

[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
　Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]田琦,蒋宁一,郑丽.265例精细个体化131I治疗Graves甲亢的疗效观察[J].国际放射医学核医学杂志,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
　Tian Qi,Jiang Ningyi,Zheng Li.Therapeutic effect of fine individual 131I treatment on Graves disease hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
[3]王越,晋建华,李思进,等.甲状腺24h摄碘率与131I治疗Graves甲亢疗效相关性研究[J].国际放射医学核医学杂志,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
　Wang Yue,Jin Jianhua,Li Sijin,et al.Correlation between thyroid 24 h of radioactive iodine uptake and clinical efficacy of 131I therapy for Graves’ hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
[4]张丽花,蒋宁一.131I治疗Graves甲亢合并肝功能损害或血细胞减少的优势与风险[J].国际放射医学核医学杂志,2015,39(6):483.[doi:10.3760/cma.j.issn.1673-4114.2015.06.010]
　Zhang Lihua,Jiang Ningyi.The advantage and risk of 131I treatment in hyperthyroidism combined with liver injury or blood cell reduction[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):483.[doi:10.3760/cma.j.issn.1673-4114.2015.06.010]
[5]胡小春,蒋宁一,李敬彦,等.硒对经131I治疗Graves病患者血清甲状腺过氧化物酶抗体水平的影响[J].国际放射医学核医学杂志,2015,39(2):140.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]
　Hu Xiaochun,Jiang Ningyi,Li Jingyan,et al.Effect of additional selenium on the levels of serum thyroid peroxidase antibody in patients with Graves disease treated with 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):140.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]
[6]查金顺,蒋艳,徐源,等.131I辅以短期小剂量碳酸锂治疗Graves甲亢的研究[J].国际放射医学核医学杂志,2014,38(1):10.[doi:10.3760/cma.j.issn 1673-4114.2014.01.003]
　Zha Jinshun,Jiang Yah,Xu Yuan,et al.Clinical research on radioiodine addition of low-doses of lithium carbonate in short-term treatment of Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(6):10.[doi:10.3760/cma.j.issn 1673-4114.2014.01.003]
[7]俞秀华,黄炜坤,林玉梅.131I治疗Graves病合并肝损害的临床观察[J].国际放射医学核医学杂志,2014,38(2):90.[doi:10.3760/cma.j.issn.1673-4114.2014.02.005]
　Yu Xiuhua,Huang Weikun,Lin Yumei.Clinical observation of 131I therapy in Graves disease patients with hepatic dysfunction[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(6):90.[doi:10.3760/cma.j.issn.1673-4114.2014.02.005]
[8]郑艳,赵德善,付松海,等.儿童和青少年Graves甲亢患者131Ⅰ治疗剂量的分析研究[J].国际放射医学核医学杂志,2013,37(2):69.[doi:10.3760/cma.j.issn.1673-4114.2013.02.002]
　ZHENG Yan,ZHAO De-shan,FU Song-hai,et al.The dose analysis of 131Ⅰ treatment in pediatric patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(6):69.[doi:10.3760/cma.j.issn.1673-4114.2013.02.002]
[9]王朝点,史育红,颜兵.TRAb水平测定在Graves眼病中的临床意义探讨[J].国际放射医学核医学杂志,2013,37(2):77.[doi:10.3760/cma.j.issn.1673-4114.2013.02.004]
　WANG Chao-dian,SHI Yu-hong,YAN Bing.The clinical value of serum thyrotrophin receptor antibody level in patients with Graves ophthalmopathy[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(6):77.[doi:10.3760/cma.j.issn.1673-4114.2013.02.004]
[10]张瑞国,秦岚,张又萍,等.初诊Graves甲亢合并肝损害及其影响因素的临床分析[J].国际放射医学核医学杂志,2013,37(5):283.[doi:10.3760/cma.j.issn.1673-4114.2013.05.008]
　ZHANG Rui-guo,QIN Lan,ZHANG You-ping,et al.Clinical study of hepatic dysfunction and its correlative factors in newly diagnosed patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(6):283.[doi:10.3760/cma.j.issn.1673-4114.2013.05.008]
[11]王深,孟召伟,贾强,等.MRI弥散加权成像、甲状腺摄碘率和血清指标测定鉴别Graves甲状腺功能亢进症和无痛性甲状腺炎的研究[J].国际放射医学核医学杂志,2014,38(6):392.[doi:10.3760/cma.j.issn.1673-4114.2014.06.011]
　Wang Shen,Meng Zhao-wei,Jia Qiang,et al.Differentiation between Graves disease and painless thyroiditis by diffusion-weighted imaging, thyroid radioactive iodine uptake and serum parameters measurement[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(6):392.[doi:10.3760/cma.j.issn.1673-4114.2014.06.011]

备注/Memo

备注/Memo:
收稿日期:2006-03-28。
通讯作者:胡晓琳,E-mail:huxiaolin@eyou.com
更新日期/Last Update: 1900-01-01